[go: up one dir, main page]

MX2011011540A - Cristales de solvato novedosos. - Google Patents

Cristales de solvato novedosos.

Info

Publication number
MX2011011540A
MX2011011540A MX2011011540A MX2011011540A MX2011011540A MX 2011011540 A MX2011011540 A MX 2011011540A MX 2011011540 A MX2011011540 A MX 2011011540A MX 2011011540 A MX2011011540 A MX 2011011540A MX 2011011540 A MX2011011540 A MX 2011011540A
Authority
MX
Mexico
Prior art keywords
solvate crystals
novel solvate
novel
crystals
olmesartan medoxomil
Prior art date
Application number
MX2011011540A
Other languages
English (en)
Inventor
Hiroshi Kiyota
Hideaki Ishikawa
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011540(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2011011540A publication Critical patent/MX2011011540A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Novedosos cristales que contienen tritilo-olmesartan-medoxomil. Se proporcionan cristales de un solvato en acetona de tritilo-olmesartan-medoxomil.
MX2011011540A 2009-04-28 2010-04-27 Cristales de solvato novedosos. MX2011011540A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009109160 2009-04-28
PCT/JP2010/057404 WO2010126014A1 (ja) 2009-04-28 2010-04-27 新規溶媒和物結晶

Publications (1)

Publication Number Publication Date
MX2011011540A true MX2011011540A (es) 2012-04-30

Family

ID=43032159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011540A MX2011011540A (es) 2009-04-28 2010-04-27 Cristales de solvato novedosos.

Country Status (19)

Country Link
US (2) US8859600B2 (es)
EP (1) EP2426127B1 (es)
JP (2) JP5697593B2 (es)
KR (1) KR20120006513A (es)
CN (1) CN102414201B (es)
AU (1) AU2010242635A1 (es)
BR (1) BRPI1013336B1 (es)
CA (1) CA2760031C (es)
CO (1) CO6470817A2 (es)
ES (1) ES2753874T3 (es)
IL (1) IL215965A0 (es)
MX (1) MX2011011540A (es)
MY (1) MY158090A (es)
NZ (1) NZ596326A (es)
RU (1) RU2563631C2 (es)
SG (2) SG10201501131SA (es)
TW (1) TWI464162B (es)
WO (1) WO2010126014A1 (es)
ZA (1) ZA201107813B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021224A2 (en) * 2009-08-19 2011-02-24 Msn Laboratories Limited Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
CN103214469B (zh) * 2013-04-29 2014-12-10 孙威 一种奥美沙坦酯化合物及其制备方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
CN110082449B (zh) * 2019-05-24 2020-05-19 珠海润都制药股份有限公司 一种奥美沙坦酯中三苯基氯甲烷的检测方法
CN113105439A (zh) * 2021-04-15 2021-07-13 迪嘉药业集团有限公司 一种小粒度奥美沙坦酯的结晶制备方法
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0282519A (ja) 1988-09-19 1990-03-23 Sanyo Electric Co Ltd 固相エピタキシャル成長方法
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
JPH0753489A (ja) * 1993-06-11 1995-02-28 Sankyo Co Ltd ビフェニルカルボキサミド誘導体の製造法
JPH07121918A (ja) 1993-08-30 1995-05-12 Tdk Corp 光磁気記録媒体
JP3521304B2 (ja) 1996-03-21 2004-04-19 東洋化成工業株式会社 １−（テトラゾリルビフェニルメチル）イミダゾール誘導体の製造方法
JP3671266B2 (ja) 1996-03-21 2005-07-13 東洋化成工業株式会社 ５−置換テトラゾール類の製造方法
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JP2004217542A (ja) 2003-01-10 2004-08-05 Fuji Photo Film Co Ltd ４，５−ジアルコキシカルボニルイミダゾールの製造方法
WO2006029057A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Purification of olmesartan medoxomil
US20070054948A1 (en) 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
JP4511550B2 (ja) 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
JP2006111586A (ja) 2004-10-15 2006-04-27 Nippon Petrochemicals Co Ltd 置換芳香族化合物の酸化方法
CA2592160A1 (en) 2005-01-03 2006-07-13 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
EP1910343B1 (en) 2005-07-29 2014-10-29 Krka Process for the preparation of olmesartan medoxomil
SI22092A (sl) 2005-07-29 2007-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo olmesartan medoksomila
WO2007047838A2 (en) * 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Process for preparing olmesartan medoxomil
CZ299902B6 (cs) 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
WO2007148344A2 (en) * 2006-06-19 2007-12-27 Matrix Laboratories Limited Process for the preparation of olmesartan medoxomil
ITMI20061848A1 (it) 2006-09-27 2008-03-28 Dipharma Spa Procedimento per la preparazione di composti feniltetrazolici
WO2008043996A2 (en) * 2006-10-09 2008-04-17 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
EP2036904A1 (en) 2007-08-08 2009-03-18 LEK Pharmaceuticals D.D. A process for the preparation of olmesartan medoxomil
CN101778843A (zh) * 2007-08-08 2010-07-14 力奇制药公司 制备奥美沙坦酯的方法
WO2009151016A1 (ja) 2008-06-09 2009-12-17 第一三共株式会社 １－ビフェニルメチルイミダゾール化合物の製造方法
WO2010026255A1 (en) 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for preparing olmesartan medoxomil intermediate
JP5595383B2 (ja) * 2009-04-28 2014-09-24 第一三共株式会社 オルメサルタンメドキソミルの製造方法
WO2011014611A2 (en) 2009-07-30 2011-02-03 Dr. Reddy's Laboratories Ltd. Preparation of olmesartan medoxomil
US20130190506A1 (en) 2010-06-28 2013-07-25 Hetero Research Foundation Process for olmesartan medoxomil

Also Published As

Publication number Publication date
RU2011148101A (ru) 2013-06-10
TW201043616A (en) 2010-12-16
JPWO2010126014A1 (ja) 2012-11-01
NZ596326A (en) 2014-02-28
CA2760031A1 (en) 2010-11-04
EP2426127B1 (en) 2019-09-04
CO6470817A2 (es) 2012-06-29
ES2753874T3 (es) 2020-04-14
US20160102079A1 (en) 2016-04-14
RU2563631C2 (ru) 2015-09-20
CA2760031C (en) 2015-03-10
CN102414201B (zh) 2015-10-14
JP2015071647A (ja) 2015-04-16
BRPI1013336A2 (pt) 2016-03-29
ZA201107813B (en) 2012-07-25
SG10201501131SA (en) 2015-04-29
IL215965A0 (en) 2012-01-31
AU2010242635A2 (en) 2014-08-07
EP2426127A1 (en) 2012-03-07
CN102414201A (zh) 2012-04-11
SG175296A1 (en) 2011-11-28
AU2010242635A1 (en) 2011-12-01
WO2010126014A1 (ja) 2010-11-04
JP5944539B2 (ja) 2016-07-05
TWI464162B (zh) 2014-12-11
MY158090A (en) 2016-08-30
EP2426127A4 (en) 2012-10-03
US20120059172A1 (en) 2012-03-08
KR20120006513A (ko) 2012-01-18
JP5697593B2 (ja) 2015-04-08
US8859600B2 (en) 2014-10-14
BRPI1013336B1 (pt) 2020-02-04

Similar Documents

Publication Publication Date Title
IN2011KN03851A (es)
MX345552B (es) Compuestos heterocíclicos útiles para inhibición de cinasa.
CR20120565A (es) Indoles
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CR20120295A (es) Triazolopiridinas
ZA201201474B (en) Signaling characteristics of an mvc operation point
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
EP2425028A4 (en) CEMENTED CARBIDE TOOLS
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IL201007A0 (en) Pulverized crystal of olmesartan medoxomil
MX2011011540A (es) Cristales de solvato novedosos.
IN2012DN00539A (es)
CL2012000278A1 (es) Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados.
SI2334668T1 (sl) Postopek priprave intermediata olmesartan medoksomila
IN2012DN03404A (es)
IN2011KN03928A (es)
MX2009010903A (es) Metodos para preparar compuestos basados en imidazol.
EP2925753A4 (en) Novel polymorphs of azilsartan medoxomil
EP2585441A4 (en) PROCESS FOR OLMESARTAN MEDOXOMIL
IL215966A0 (en) Method for producing olmesartan medoxomil
GB0710680D0 (en) Novel crystalline form of olmesartan medoxmil
MY183201A (en) Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds
AP2011005999A0 (en) Process for the preparation of olmesartan medoxomil.
IL213935A0 (en) Novel heterocyclic compounds as metap-2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration